Company · CIK 1693011
Inozyme Pharma, Inc.
| CIK | 1693011 (SEC EDGAR) |
|---|---|
| Industry (SIC) | 2834 — Pharmaceutical Preparations |
| Incorporated in | DE |
| Business address | MA |
| Listed | no ticker on SEC record today |
| First annual or quarterly report | 2020-09-03 |
Offerings
3 registrations| Registration | Label and status | First filed | Last event | Filings |
|---|---|---|---|---|
| 333-258702 | 2021-08-11 | 2025-07-01 | 6 | |
| 333-275364 | 2023-11-07 | 2025-07-01 | 4 | |
| 333-239648 | 2020-07-02 | 2020-07-24 | 6 |
Filings
17| Filed | Filing | Registration | Accession |
|---|---|---|---|
| 2025-07-01 | EFFECTDeclared effective | 333-275364 | 9999999995-25-002117 |
| 2025-07-01 | EFFECTDeclared effective | 333-258702 | 9999999995-25-002110 |
| 2024-08-06 | 424B5Shelf takedown | 333-275364 | 0001193125-24-194954 |
| 2023-11-15 | EFFECTDeclared effective | 333-275364 | 9999999995-23-003337 |
| 2023-11-07 | S-3Shelf registered | 333-275364 | 0001193125-23-272415 |
| 2023-07-28 | 424B5Shelf takedown | 333-258702 | 0001193125-23-197820 |
| 2023-07-27 | 424B5Shelf takedown | 333-258702 | 0001193125-23-196281 |
| 2022-04-14 | 424B5Shelf takedown | 333-258702 | 0001193125-22-105747 |
| 2021-08-23 | EFFECTDeclared effective | 333-258702 | 9999999995-21-003279 |
| 2021-08-11 | S-3Shelf registered | 333-258702 | 0001193125-21-242618 |
| 2020-07-24 | 424B4Final prospectus | 333-239648 | 0001193125-20-198533 |
| 2020-07-23 | EFFECTDeclared effective | 333-239648 | 9999999995-20-001902 |
| 2020-07-23 | S-1/AAmendment | 333-239648 | 0001193125-20-197525 |
| 2020-07-22 | S-1/AAmendment | 333-239648 | 0001193125-20-196740 |
| 2020-07-20 | S-1/AAmendment | 333-239648 | 0001193125-20-195044 |
| 2020-07-02 | S-1Registration filed | 333-239648 | 0001193125-20-186800 |
| 2020-05-08 | DRSDraft made public | 377-03163 | 0000950123-20-004197 |